268 related articles for article (PubMed ID: 15698606)
1. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.
Hu YF; He J; Chen GL; Wang D; Liu ZQ; Zhang C; Duan LF; Zhou HH
Clin Chim Acta; 2005 Mar; 353(1-2):187-92. PubMed ID: 15698606
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 (CYP3A4*18) and glutathione-S-transferase (GSTP1) polymorphisms in a healthy Tunisian population.
Zaied C; Abid S; Mtiraoui N; Zellema D; Achour A; Bacha H
Genet Test Mol Biomarkers; 2012 Oct; 16(10):1184-7. PubMed ID: 22971138
[TBL] [Abstract][Full Text] [Related]
3. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
4. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
[TBL] [Abstract][Full Text] [Related]
5. CYP3A5 variant allele frequencies in Dutch Caucasians.
van Schaik RH; van der Heiden IP; van den Anker JN; Lindemans J
Clin Chem; 2002 Oct; 48(10):1668-71. PubMed ID: 12324482
[TBL] [Abstract][Full Text] [Related]
6. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
Garsa AA; McLeod HL; Marsh S
BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
[TBL] [Abstract][Full Text] [Related]
7. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
8. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.
Hiratsuka M; Takekuma Y; Endo N; Narahara K; Hamdy SI; Kishikawa Y; Matsuura M; Agatsuma Y; Inoue T; Mizugaki M
Eur J Clin Pharmacol; 2002 Sep; 58(6):417-21. PubMed ID: 12242601
[TBL] [Abstract][Full Text] [Related]
9. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.
Semiz S; Dujić T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Mlinar B; Marc J; Causević A
Med Glas (Zenica); 2011 Feb; 8(1):84-9. PubMed ID: 21263403
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups.
Li D; Zhang GL; Lou YQ; Li Q; Wang X; Bu XY
J Clin Pharm Ther; 2007 Feb; 32(1):89-95. PubMed ID: 17286792
[TBL] [Abstract][Full Text] [Related]
11. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.
Yousef AM; Bulatova NR; Newman W; Hakooz N; Ismail S; Qusa H; Zahran F; Anwar Ababneh N; Hasan F; Zaloom I; Khayat G; Al-Zmili R; Naffa R; Al-Diab O
Mol Biol Rep; 2012 Oct; 39(10):9423-33. PubMed ID: 22722998
[TBL] [Abstract][Full Text] [Related]
12. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.
Lee SJ; Goldstein JA
Pharmacogenomics; 2005 Jun; 6(4):357-71. PubMed ID: 16004554
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.
Krishnakumar D; Gurusamy U; Dhandapani K; Surendiran A; Baghel R; Kukreti R; Gangadhar R; Prayaga U; Manjunath S; Adithan C
Fundam Clin Pharmacol; 2012 Apr; 26(2):295-306. PubMed ID: 21265876
[TBL] [Abstract][Full Text] [Related]
14. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.
Liu CH; Peck K; Huang JD; Lin MS; Wang CH; Hsu WP; Wang HW; Lee HL; Lai ML
Pharmacogenomics; 2005 Oct; 6(7):731-47. PubMed ID: 16207150
[TBL] [Abstract][Full Text] [Related]
15. CYP3A5*3 and MDR-1 C3435T single nucleotide polymorphisms in six Chinese ethnic groups.
Lai Y; Zhang J; Wang YX; Wang XD; Li JL; Wang YH; Zeng YJ; Huang M
Pharmazie; 2011 Feb; 66(2):136-40. PubMed ID: 21434577
[TBL] [Abstract][Full Text] [Related]
16. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations.
Balram C; Zhou Q; Cheung YB; Lee EJ
Eur J Clin Pharmacol; 2003 Jun; 59(2):123-6. PubMed ID: 12756511
[TBL] [Abstract][Full Text] [Related]
17. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population.
Fukuen S; Fukuda T; Maune H; Ikenaga Y; Yamamoto I; Inaba T; Azuma J
Pharmacogenetics; 2002 Jun; 12(4):331-4. PubMed ID: 12042671
[TBL] [Abstract][Full Text] [Related]
18. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
19. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
20. Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem.
Yamamoto T; Kubota T; Ozeki T; Sawada M; Yokota S; Yamada Y; Kumagai Y; Iga T
Clin Chim Acta; 2005 Dec; 362(1-2):147-54. PubMed ID: 16024008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]